Results 221 to 230 of about 221,455 (333)

Chemoimmunotherapy-associated CD20 (<i>MS4A1</i>) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20-directed cellular therapies. [PDF]

Hemasphere
Guijosa A, Tsakmaklis N, Dhe-Paganon S, Garbicz F, Carrasco R, Hatcher J, Ramirez-Gamero A, Pizzarella D, Kofides A, Liu S, Sun H, Liu X, Guerrera ML, Branagan AR, von Keudell G, Sarosiek SR, Castillo JJ, Hunter ZR, Treon SP.   +18 more
europepmc   +1 more source

Early Remission of Cerebrospinal Fluid Interleukin‐6 After Initial Immunotherapy Predicts a Good Prognosis in Autoimmune Encephalitis

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT Background Autoimmune encephalitis therapy requires adjusting the regimen based on therapeutic response; however, clinical indicators of this response remain unknown. Aim To determine the predictive capability of cerebrospinal fluid (CSF), electroencephalography (EEG), and brain magnetic resonance imaging (MRI) in identifying responders to ...
Yuta Madokoro, Yuto Uchida, Hiroyasu Inoue, Toyohiro Sato, Teppei Fujioka, Masayuki Mizuno, Shoji Kawashima, Masahiro Oomura, Noriyuki Matsukawa   +8 more
wiley   +1 more source

Effectiveness and safety of efgartigimod in patients with anti‐NMDAR or anti‐LGI1 encephalitis and its 18F‐DPA714 PET imaging evaluation: A multicenter, single‐arm, prospective, observational real‐world study

Neuroprotection, EarlyView.
Abstract Background Efgartigimod disrupts the recycling of pathogenic IgG autoantibodies and may represent a candidate therapy for autoimmune encephalitis. This real‐world study evaluated the clinical efficacy, safety, and impact of efgartigimod on brain inflammation.
Huanyu Meng, Siqi Tu, Yifan Zhou, Ruinan Shen, Xiaoyu Chen, Zhaozhao Cheng, Limei Wang, Yan Wu, Jie Lu, Shengjun Wang, Yan Xu, Wanhui Lin, Sheng Chen   +12 more
wiley   +1 more source

In‐frame variants in TP53 gene identified in adult leukemia samples are predominantly deleterious: a study of the TP53 Network of Education and Research Initiative on CLL

The Journal of Pathology, EarlyView.
Abstract The prognostic and predictive impact of TP53 variants in leukemia led to their inclusion in diagnostic and treatment guidelines, increasing the demand for rapid, reliable laboratory analysis, interpretation, and reporting. While most TP53 variants identified in tumor samples can be interpreted using data from large‐scale functional studies ...
Šárka Pavlová, Johana Gombíková, Silvia Petrezsélyová, Libor Macůrek, Marcela Ženatová, Marie Zádrapová, Anna Panovská, Eva Zapletalová, Blanca Ferrer Lores, Alicia Serrano Alcalá, Eugen Tausch, Stephan Stilgenbauer, Fanny Baran‐Marszak, Gregory Lazarian, Miguel Alcoceba, Ana Balanzategui, Lisa Bonello, Ivana Ježíšková, Martina Sopkovičová, Silvia Zibellini, Marzia Varettoni, Audrey Bidet, Helena Podgornik, Sandra Šućurović, Riccardo Moia, Mónica López‐Guerra, Mark Catherwood, Šárka Pospíšilová, Jitka Malčíková   +28 more
wiley   +1 more source

Precision immunomodulation for pediatric hemophagocytic lymphohistiocytosis in intensive care

Pediatric Investigation, EarlyView.
This review presents a bedside framework for recognizing pediatric hemophagocytic lymphohistiocytosis and cytokine storm, stabilizing organ dysfunction, identifying the underlying phenotype, selecting targeted immunomodulation, considering extracorporeal adjuncts, and reassessing response within 24–72 h. ABSTRACT Hemophagocytic lymphohistiocytosis (HLH)
Weerapong Lilitwat, Prakreeti Bhandari
wiley   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Pregnancy in CTD‐interstitial lung disease: Current evidence, clinical challenges, and a proposed management algorithm

Rheumatology &Autoimmunity, EarlyView.
Summary of pregnancy management in CTD‐ILD across preconception, antenatal, and postpartum phases, emphasizing risk stratification and multidisciplinary care. 6MWT, 6‐min walk test; CTD‐ILD: connective tissue disease‐interstitial lung disease; DLCO, diffusion capacity of the lung for carbon monoxide; FVC, forced vital capacity; MDT, multidisciplinary ...
Khaled Aldhuaina, Ghaydaa Aldabie, Mohammad Abdulsalam, Ali Jawad   +3 more
wiley   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Deficiency of high‐molecular‐weight von Willebrand factor mitigates thrombo‐complement injury in an LPS‐induced TMA‐like mouse model

VIEW, EarlyView.
Reduction of high‐molecular‐weight von Willebrand factor disrupts the platelet–complement amplification loop, attenuating microvascular thrombosis, complement deposition, endothelial injury, and organ damage in complement‐mediated thrombotic microangiopathy.
Yang Li, Chihao Zhang, Xiaoqian Xu, Sicong Wang, Xiaofan Hu, Junjie Yao, Xi Wu, Difeng Zhu, Qian Liang, Yeling Lu, Yu Liu, Guanqun Xu, Jiakuan Zhou, Qiulan Ding, Wenman Wu, Ya Li, Jing Dai, Xuefeng Wang   +17 more
wiley   +1 more source

Medication Related Osteonecrosis of the Jaw: Knowledge, Attitudes and Practice Patterns Among Australian Dental Practitioners

Australian Dental Journal, EarlyView.
ABSTRACT Background Medication related osteonecrosis of the jaw (MRONJ) is a debilitating condition associated with antiresorptive and antiangiogenic therapies. As the use of these medications continues to increase, dental practitioners play a critical role in prevention and management of at‐risk patients. This survey evaluated the awareness, knowledge
Ying Shi Chang, Christopher Friel, Gary Low, Albert Yaacoub, Stephen Clive Cox   +4 more
wiley   +1 more source